Citation | Population | Dosing | Duration | Results |
---|---|---|---|---|
Aman et al 2002 [8] | 118 children aged 5–12 with DBDs and subaverage IQ | 0.02–0.06 mg/kg/day RIS or PBO | 6 weeks | Significant improvements over PBO by week 1 on the NCBRF conduct problem subscale; significant improvement over PBO on all other NCBRF subscales |
Snyder et al 2002 [9] | 110 children aged 5–12 with DBDs and subaverage IQ | 0.02–0.06 mg/kg/day RIS or PBO | 6 weeks | Significant improvements over PBO by week 1 on the NCBRF conduct problem subscale; significant improvement over PBO on all other NCBRF subscales |
Findling et al 2004 [11] | 107 children aged 5–14 with DBDs and subaverage IQ previously participating in a 6-week DB study | 0.02–0.06 mg/kg/day RIS (mean dose, 1.64 mg/day) | 1-year OL extension | Significant improvements on the NCBRF conduct problem subscale, most notably during the first 4 weeks; significant change from baseline on all other NCBRF subscales |
Turgay et al 2002 [15] | 77 children aged 5–12 with DBDs and subaverage previously participating in a 6-week DB study | 0.02–0.06 mg/kg/day RIS (mean dose, 2.38 mg/day) | 48-week OL extension | Significant improvements on the NCBRF conduct problem subscale in subjects previously receiving PBO in DB study; improvements were maintained in subjects previously treated with risperidone during DB study |
Croonenberghs et al 2005 [10] | 504 children aged 5–14 years with DBDs and subaverage IQ | 0.02–0.06 mg/kg/day RIS (mean dose, 1.6 ± 0.03 mg/day) | 1 year | Significant improvement on the NCBRF conduct problem subscale over baseline as early as week 1; improvements were maintained over the course of the study |
Reyes et al 2006 [13] | 48 children from [10] aged 7 to 15 with DBDs, subaverage IQ, and comorbid ADHD | 0.02–0.06 mg/kg/day (mean dose, 1.83 mg/day) | 12-month OL extension of Findling et al | Significant improvements on the NCBRF conduct problem subscale were maintained through the second year of treatment |
Reyes et al 2006 [14] | 35 children from [10] aged 5–15 years with DBDs, subaverage IQ, and comorbid ADHD | 0.02–0.06 mg/kg/day (mean dose, 1.92 mg/day) | 24-month OL extension of Findling et al | Symptoms continued to be well controlled, as measured by CGI |